Macrocyclic HCV NS3 Protease Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection are limited in clinical benefit, and there is a need for more effective therapeutic agents to combat chronic HCV infection, as existing therapies rely on immunotherapy with interferon-α and ribavirin, with no established vaccine available.
Innovation Solution
Development of novel macrocyclic compounds that inhibit the HCV NS3 protease, which can be used alone or in combination with other antivirals, immunomodulators, or vaccines to treat or prevent HCV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy with interferon-α and ribavirin is used, then HCV infection can be treated, but clinical benefit is limited and no established vaccine is available
Solution Approach 1:
The patent changes the molecular parameters of the protease inhibitor compounds, optimizing their structure to achieve higher binding affinity and catalytic inhibition against HCV NS3 protease, thereby improving clinical benefit beyond existing interferon-based therapies
Solution Approach 2:
The invention combines multiple functional groups within the macrocyclic compound structure to create a multi-functional inhibitor that simultaneously binds to the protease active site and prevents viral replication, enhancing both reliability and treatment versatility
2Reliability
If current antiviral therapies are used, then HCV infection can be combated, but the mechanism of action is limited and resistance may develop
Solution Approach 1:
The patent divides the inhibition mechanism into distinct functional segments: binding to the protease active site, preventing substrate access, and blocking catalytic activity, thereby enhancing effectiveness while maintaining a manageable mechanistic complexity
Solution Approach 2:
The macrocyclic compound acts as an intermediary between the viral protease and the viral replication process, blocking the protease function without directly attacking the virus itself, which improves effectiveness and reduces resistance development
Data Source
AI summary
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.